Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580785 | 0.88 | NPSR1 (0.46) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL2657319 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL8436651 | 0.82 | TRPA1 (0.41) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL30655473 | 0.82 | TRPA1 (0.41) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL10263919 | 0.79 | NPSR1 (0.50) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL333551 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL29418197 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL11244115 | 0.79 | KDM4E (0.49) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 | |
| SCHEMBL126441 | 0.78 | TRPA1 (0.46) | CYP1A2TRPA1CYP2A6ALDH1A1TAAR1 | |
| SCHEMBL4798301 | 0.78 | TRPA1 (0.46) | CYP1A2CYP2C9CYP2C19CYP2D6NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| CN-110461839-A | JAK inhibitor containing 4 membered heterocyclic amides | THERAVANCE BIOPHARMA R&D IP LLC | 2019-11-15 | — | — | CN | disclosed |
| CN-110382498-A | Fused imidazole-piperidine JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2019-10-25 | — | — | CN | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006062972-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | CYP1A2 2052/4885CYP2C9 4604/4885CYP2C19 4507/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | CYP1A2 409/4885CYP2C9 81/4885CYP2C19 268/4885 |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | CYP1A2 676/4885CYP2C9 1657/4885CYP2C19 1381/4885 |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | NR4A3, NR0B1, NR2C2 | CYP1A2 676/4885CYP2C9 1657/4885CYP2C19 1381/4885 |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | CYP1A2 1513/4885CYP2C9 642/4885CYP2C19 1123/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | CYP1A2 2052/4885CYP2C9 4604/4885CYP2C19 4507/4885 |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | TFPI, F7, HABP2 | CYP1A2 1374/4885CYP2C9 421/4885CYP2C19 682/4885 |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | NR0B1, NR4A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP1A2 605/4885CYP2C9 1249/4885CYP2C19 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.